Shatha AbuHammad
Shatha AbuHammad
Dana-Farber Cancer Institute
Verified email at dfci.harvard.edu
Title
Cited by
Cited by
Year
Gene expression alterations in doxorubicin resistant MCF7 breast cancer cell line
S AbuHammad, M Zihlif
Genomics 101 (4), 213-220, 2013
1492013
Narghile (water pipe) smoking among university students in Jordan: prevalence, pattern and beliefs
NS Dar-Odeh, FG Bakri, MK Al-Omiri, HM Al-Mashni, HA Eimar, ...
Harm reduction journal 7 (1), 1-6, 2010
1192010
Palbociclib synergizes with BRAF and MEK inhibitors in treatment nave melanoma but not after the development of BRAF inhibitor resistance
CA Martin, C Cullinane, L Kirby, S Abuhammad, EJ Lelliott, K Waldeck, ...
International journal of cancer 142 (10), 2139-2152, 2018
382018
Regulation of PRMT5–MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma
S AbuHammad, C Cullinane, C Martin, Z Bacolas, T Ward, H Chen, ...
Proceedings of the National Academy of Sciences 116 (36), 17990-18000, 2019
352019
Differential expression and androgen regulation of microRNAs and metalloprotease 13 in breast cancer cells
M Ahram, E Mustafa, R Zaza, S Abu Hammad, M Alhudhud, R Bawadi, ...
Cell biology international 41 (12), 1345-1355, 2017
222017
Predicting recurrent aphthous ulceration using genetic algorithms-optimized neural networks
NS Dar-Odeh, OM Alsmadi, F Bakri, Z Abu-Hammour, AA Shehabi, ...
Advances and applications in bioinformatics and chemistry: AABC 3, 7, 2010
182010
Flare-up of rheumatoid arthritis by anti-CTLA-4 antibody but not by anti-PD1 therapy in a patient with metastatic melanoma
NF Jaberg-Bentele, M Kunz, S Abuhammad, R Dummer
Case reports in dermatology 9 (1), 65-68, 2017
132017
A novel immunogenic mouse model of melanoma for the preclinical assessment of combination targeted and immune-based therapy
EJ Lelliott, C Cullinane, CA Martin, R Walker, KM Ramsbottom, ...
Scientific reports 9 (1), 1-10, 2019
82019
The cellular and molecular effects of the androgen receptor agonist, Cl-4AS-1, on breast cancer cells
M Ahram, E Mustafa, S Abu Hammad, M Alhudhud, R Bawadi, ...
Endocrine research 43 (3), 203-214, 2018
52018
Inhibitory effects of new mercapto xanthine derivatives in human mcf7 and k562 cancer cell lines
HN Sultani, RA Ghazal, AM Hayallah, LK Abdulrahman, K Abu‐Hammour, ...
Journal of Heterocyclic Chemistry 54 (1), 450-456, 2017
52017
CDK4/6 inhibition in cancer: the cell cycle splicing connection
KE Sheppard, S AbuHammad
Molecular & cellular oncology 6 (6), e1673643, 2019
32019
Integrative clinical and molecular characterization of translocation renal cell carcinoma
Z Bakouny, A Sadagopan, P Ravi, NY Metaferia, J Li, S AbuHammad, ...
bioRxiv, 2021
22021
A genome-scale CRISPR screen reveals PRMT1 as a critical regulator of androgen receptor signaling in prostate cancer
S Tang, NY Metaferia, MF Nogueira, MK Gelbard, S Abou Alaiwi, JH Seo, ...
BioRxiv, 2020
22020
CDK4/6 Inhibition Reprograms Mitochondrial Metabolism in BRAFV600 Melanoma via a p53 Dependent Pathway
NT Santiappillai, S Abuhammad, A Slater, L Kirby, GA McArthur, ...
Cancers 13 (3), 524, 2021
2021
Genome-scale genetic screening identifies PRMT1 as a critical vulnerability in castration-resistant prostate cancer
S Tang, N Metaferia, M Nogueira, M Gelbard, S Abou Alaiwi, JH Seo, ...
European Journal of Cancer 138, S7, 2020
2020
Regulation of PRMT5-MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma (vol 116, pg 17990, 2019)
S AbuHammad, C Cullinane, C Martin, Z Bacolas, T Ward, H Chen, ...
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF…, 2020
2020
Abstract A061: Targeting PRMT5 enhances the response to CDK4/6 inhibitors in multiple cancer types
S AbuHammad, GA McArthur, K Sheppard
Molecular Cancer Therapeutics 18 (12 Supplement), A061-A061, 2019
2019
Targeting cyclin dependent kinase 4 (CDK4) in melanoma: mechanisms of resistance and novel combination therapies
S AbuHammad
2018
The system can't perform the operation now. Try again later.
Articles 1–18